Business barriers slowing the pace of cancer immunotherapy research and development.
Tuma
Rabiya S
RS
D000276:Adjuvants, Immunologic / Q000191:economics; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics; D035843:Biomedical Research / Q000191:economics*; D019496:Cancer Vaccines / Q000191:economics; D017277:Drug Approval; D015195:Drug Design; D004345:Drug Industry; D015507:Drugs, Investigational / Q000009:adverse effects / Q000191:economics; D005380:Financing, Government; D006801:Humans; D007167:Immunotherapy / Q000191:economics*; D008297:Male; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000191:economics* / Q000276:immunology / Q000628:therapy*; D011471:Prostatic Neoplasms / Q000191:economics / Q000628:therapy; D014481:United States; D014486:United States Food and Drug Administration
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D015507:Drugs, Investigational